ReviewHealth science reports2025
Influencing Factors of Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients: A Meta-Analysis.
Review in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a nomogram for predicting the probability of medication adherence to adjuvant endocrine therapy in breast cancer patients: a predictive modeling study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Adherence to adjuvant endocrine therapy (AET) in breast cancer patients is affected by multiple factors. A number of studies were performed to find out the potential influencing factors. However, the results of these studies were not consistent. Therefore, this meta-analysis aimed to synthesize the existing evidence on influencing factors of AET adherence in breast cancer patients. Methods: Several databases were searched for published and unpublished studies. The potential influencing factors were identified and mapped to the five dimensions of the World Health Organization (WHO) medication adherence theoretical framework. Odds ratios (OR) and 95% confidence intervals (95% CI) were used to evaluate the influencing factors, and then meta-analysis was performed using Review Manager 5.4 software. Results: Thirty-seven eligible studies were included, with a total of 104,777 patients. Nineteen influencing factors were divided into five categories: patient-related factors (OR = 1.74, 95% CI: 1.55-1.96), therapy-related factors (OR = 2.13, 95% CI: 1.85-2.46), disease-related factors (OR = 1.38, 95% CI: 1.25-1.52), socioeconomic factors (OR = 1.34, 95% CI: 1.20-1.50) and health system-related factors (OR = 0.46, 95% CI: 0.26-0.81). Age < 50 years, age > 65 years, lack of knowledge about AET, side effects, without radiotherapy or chemotherapy, initial use of tamoxifen, switching AET, complementary or alternative treatment use, higher Charlson comorbidity index, taking multiple medications, depression, lower income, no medical insurance, no partner, and lack of social support were related to non-adherence. A higher level of medical support was related to good adherence. Conclusion: AET adherence is influenced by multiple factors. This meta-analysis synthesizes existing evidence on influencing factors for AET adherence in breast cancer patients, offering a comprehensive overview. Governments and stakeholders should align health policy or interventions with the WHO five dimensions of medication adherence to enhance tailored AET adherence strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.